title: Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.
abstract: Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m(2) i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.
authors.affiliation: Department of Odontostomatology and Maxillo-Facial Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: Francini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Pascucci
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
authors.forename: Gianluca
authors.initials: G
authors.lastname: Bargagli
authors.forename: Raffaele
authors.initials: R
authors.lastname: Conca
authors.forename: Antonella
authors.initials: A
authors.lastname: Licchetta
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.forename: Ignazio
authors.initials: I
authors.lastname: Martellucci
authors.forename: Giorgio
authors.initials: G
authors.lastname: Chiriacò
authors.forename: Salvatora Tindara
authors.initials: ST
authors.lastname: Miano
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Marzocca
authors.forename: Antonio
authors.initials: A
authors.lastname: Manganelli
authors.forename: Roberto
authors.initials: R
authors.lastname: Ponchietti
authors.forename: Vinno
authors.initials: V
authors.lastname: Savelli
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
references.citation: Eur J Cancer. 2005 May;41(8):1117-26
references.pmid: 15911234
references.citation: Pain. 1975 Sep;1(3):277-299
references.pmid: 1235985
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8247-52
references.pmid: 16278480
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1439-46
references.pmid: 15735119
references.citation: J Fam Pract. 1992 Feb;34(2):160-4
references.pmid: 1371139
references.citation: BJU Int. 2007 Oct;100(4):775-9
references.pmid: 17535276
references.citation: Br J Cancer. 2011 Feb 15;104(4):613-9
references.pmid: 21285986
references.citation: Urol Oncol. 2006 May-Jun;24(3):250-3
references.pmid: 16678059
references.citation: Cancer Res. 2008 Nov 1;68(21):9033-40
references.pmid: 18974149
references.citation: Eur Urol. 2008 Nov;54(5):1089-94
references.pmid: 18276061
references.citation: Eur J Cancer. 2010 Jul;46(10):1770-2
references.pmid: 20483588
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3942-50
references.pmid: 17606728
references.citation: J Urol. 2007 Sep;178(3 Pt 2):S36-41
references.pmid: 17644120
references.citation: Expert Rev Anticancer Ther. 2007 Apr;7(4):433-45
references.pmid: 17428164
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6850; author reply 6850-1
references.pmid: 18006788
references.citation: Prostate. 2009 Dec 1;69(16):1802-7
references.pmid: 19676083
references.citation: Prostate. 1998 Apr 1;35(1):1-10
references.pmid: 9537593
references.citation: Clin Cancer Res. 2007 May 1;13(9):2804-10
references.pmid: 17473214
references.citation: Gynecol Oncol. 2006 Aug;102(2):134-9
references.pmid: 16527339
references.citation: Clin Cancer Res. 2006 May 15;12(10):3124-9
references.pmid: 16707611
references.citation: J Clin Oncol. 2005 Sep 1;23(25):6139-48
references.pmid: 16135480
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: Clin Adv Hematol Oncol. 2008 Feb;6(2):118-22, 127-32
references.pmid: 18347563
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: Pain. 1988 Apr;33(1):53-62
references.pmid: 3380551
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1488-92
references.pmid: 17332293
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: BJU Int. 2005 Nov;96(7):990-4
references.pmid: 16225514
references.citation: Ann Oncol. 2008 Jul;19(7):1308-1311
references.pmid: 18356135
references.citation: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references.pmid: 18309951
references.citation: Urology. 2006 Jun;67(6):1235-40
references.pmid: 16765185
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437